Literature DB >> 12542396

Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.

Kerry Gordon1, Pierre Redelinghuys, Sylva L U Schwager, Mario R W Ehlers, Anastassios C Papageorgiou, Ramanathan Natesh, K Ravi Acharya, Edward D Sturrock.   

Abstract

Angiotensin I-converting enzyme (ACE) is a highly glycosylated type I integral membrane protein. A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity. Whereas underglycosylated glycoforms showed differences in expression and processing, their kinetic parameters were similar to that of native tACE. N-glycosylation of Asn-72 or Asn-109 was necessary and sufficient for the production of enzymically active tACE but glycosylation of Asn-90 alone resulted in rapid intracellular degradation. All mutants showed similar levels of phorbol ester stimulation and were solubilized at the same juxtamembrane cleavage site as the native enzyme. Two mutants, tACEDelta36-g1234 and -g13, were successfully crystallized, diffracting to 2.8 and 3.0 A resolution respectively. Furthermore, a truncated, soluble tACE (tACEDelta36NJ), expressed in the presence of the glucosidase-I inhibitor N -butyldeoxynojirimycin, retained the activity of the native enzyme and yielded crystals belonging to the orthorhombic P2(1)2(1)2(1) space group (cell dimensions, a=56.47 A, b=84.90 A, c=133.99 A, alpha=90 degrees, beta=90 degrees and gamma=90 degrees ). These crystals diffracted to 2.0 A resolution. Thus underglycosylated human tACE mutants, lacking O-linked oligosaccharides and most N-linked oligosaccharides or with only simple N-linked oligosaccharides attached throughout the molecule, are suitable for X-ray diffraction studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542396      PMCID: PMC1223310          DOI: 10.1042/BJ20021842

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  19 in total

1.  Role of asparagine-linked oligosaccharides in the function of the rat PTH/PTHrP receptor.

Authors:  A T Zhou; I Assil; A B Abou-Samra
Journal:  Biochemistry       Date:  2000-05-30       Impact factor: 3.162

2.  Ligand binding by the immunoglobulin superfamily recognition molecule CD2 is glycosylation-independent.

Authors:  S J Davis; E A Davies; A N Barclay; S Daenke; D L Bodian; E Y Jones; D I Stuart; T D Butters; R A Dwek; P A van der Merwe
Journal:  J Biol Chem       Date:  1995-01-06       Impact factor: 5.157

3.  Different glycosylation requirements for the synthesis of enzymatically active angiotensin-converting enzyme in mammalian cells and yeast.

Authors:  R Sadhukhan; I Sen
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

4.  Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules.

Authors:  C L Waller; G R Marshall
Journal:  J Med Chem       Date:  1993-08-06       Impact factor: 7.446

5.  Mapping the active site of angiotensin-converting enzyme by transferred NOE spectroscopy.

Authors:  M Mayer; B Meyer
Journal:  J Med Chem       Date:  2000-06-01       Impact factor: 7.446

6.  Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization.

Authors:  Florian Nachon; Yvain Nicolet; Nathalie Viguié; Patrick Masson; Juan C Fontecilla-Camps; Oksana Lockridge
Journal:  Eur J Biochem       Date:  2002-01

7.  Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.

Authors:  M R Ehlers; E A Fox; D J Strydom; J F Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Angiotensin-converting enzyme 2 is an essential regulator of heart function.

Authors:  Michael A Crackower; Renu Sarao; Gavin Y Oudit; Chana Yagil; Ivona Kozieradzki; Sam E Scanga; Antonio J Oliveira-dos-Santos; Joan da Costa; Liyong Zhang; York Pei; James Scholey; Carlos M Ferrario; Armen S Manoukian; Mark C Chappell; Peter H Backx; Yoram Yagil; Josef M Penninger
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

9.  Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.

Authors:  Ramanathan Natesh; Sylva L U Schwager; Edward D Sturrock; K Ravi Acharya
Journal:  Nature       Date:  2003-01-19       Impact factor: 49.962

10.  The unique N-terminal sequence of testis angiotensin-converting enzyme is heavily O-glycosylated and unessential for activity or stability.

Authors:  M R Ehlers; Y N Chen; J F Riordan
Journal:  Biochem Biophys Res Commun       Date:  1992-02-28       Impact factor: 3.575

View more
  28 in total

1.  Application of protein engineering to enhance crystallizability and improve crystal properties.

Authors:  Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-04-21

Review 2.  Interacting cogs in the machinery of the renin angiotensin system.

Authors:  Lizelle Lubbe; Edward D Sturrock
Journal:  Biophys Rev       Date:  2019-06-08

Review 3.  Can the propensity of protein crystallization be increased by using systematic screening with metals?

Authors:  Raghurama P Hegde; Gowribidanur C Pavithra; Debayan Dey; Steven C Almo; S Ramakumar; Udupi A Ramagopal
Journal:  Protein Sci       Date:  2017-06-29       Impact factor: 6.725

4.  Structure of testis ACE glycosylation mutants and evidence for conserved domain movement.

Authors:  Jean M Watermeyer; B Trevor Sewell; Sylva L Schwager; Ramanathan Natesh; Hazel R Corradi; K Ravi Acharya; Edward D Sturrock
Journal:  Biochemistry       Date:  2006-10-24       Impact factor: 3.162

5.  An approach to crystallizing proteins by metal-mediated synthetic symmetrization.

Authors:  Arthur Laganowsky; Minglei Zhao; Angela B Soriaga; Michael R Sawaya; Duilio Cascio; Todd O Yeates
Journal:  Protein Sci       Date:  2011-09-30       Impact factor: 6.725

Review 6.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

7.  Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain.

Authors:  Sergei M Danilov; Sergey Kalinin; Zhenlong Chen; Elena I Vinokour; Andrew B Nesterovitch; David E Schwartz; Olivier Gribouval; Marie-Claire Gubler; Richard D Minshall
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

8.  The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.

Authors:  Colin S Anthony; Hazel R Corradi; Sylva L U Schwager; Pierre Redelinghuys; Dimitris Georgiadis; Vincent Dive; K Ravi Acharya; Edward D Sturrock
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

9.  Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.

Authors:  Dongning Wang; Slava Zaitsev; Garry Taylor; Alessandra d'Azzo; Erik Bonten
Journal:  Biochim Biophys Acta       Date:  2009-04

10.  Functional regulation of sugar assimilation by N-glycan-specific interaction of pancreatic α-amylase with glycoproteins of duodenal brush border membrane.

Authors:  Kimie Asanuma-Date; Yuki Hirano; Na Le; Kotone Sano; Nana Kawasaki; Noritaka Hashii; Yoko Hiruta; Ken-ichi Nakayama; Mariko Umemura; Kazuhiko Ishikawa; Hiromi Sakagami; Haruko Ogawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.